Diabetes

FDA Fast Tracks Empagliflozin to Improve Outcomes Following Heart Attack

September 18, 2020

Data showed that empagliflozin with standard of care was superior to placebo in reducing the risk of CV death or hospitalization.

FDA Approves New Doses of Dulaglutide for the Treatment of Type 2 Diabetes

September 08, 2020

Approval was based on a phase 3 clinical trial comparing the investigative doses with the approved 1.5 mg dose.

FDA OKs Hybrid Closed Loop Diabetes Management Device for Use in Young Children

September 01, 2020

The MiniMed 770G system (Medtronic) is approved for use by individuals aged 2 to 6 with type 1 diabetes.

Dapagliflozin Reduces Risk of Kidney Failure, Death in Chronic Kidney Disease

August 31, 2020

Dapagliflozin (Farxiga; AstraZeneca) demonstrated positive results in the phase 3 DAPA-CKD trial.

FDA Removes Boxed Warning for Amputation Risk From Canagliflozin

August 27, 2020

The removal of the boxed warning from canagliflozin was based on the FDA’s review of new data from 3 clinical trials.

Metabolic Syndrome Linked to Increased Risk of COVID-19 Mortality

August 26, 2020

Individuals with metabolic syndrome who were hospitalized for COVID-19 were more likely to experience worse outcomes.

Bayshore Recalls 2 Lots of Extended-Release Metformin

August 21, 2020

Bayshore Pharmaceuticals issued a voluntary recall of 2 lots of its extended-release metformin products due to high levels of NDMA.

Lilly Expands Insulin Affordability Solutions

August 11, 2020

Lilly is committed to helping people who face high out-of-pocket costs for insulin by offering a broad suite of affordable solutions.

Youth Involvement in Decision to Start CGM Linked to Consistent Use

August 04, 2020

Youth with diabetes who are involved in the decision to start continuous glucose monitoring reported consistent use 2 months after starting.

COVID-19 Effects on Patients with Diabetes

July 31, 2020

Joshua Miller, MD MPH and medical director of diabetes care for Stony Brook Medicine, discusses continuous glucose monitoring (CGM) technology, which the FDA has authorized for use in hospitals amid the COVID-19 pandemic.